Key terms
About PLUR
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PLUR news
Apr 08
7:21am ET
Pluri granted U.S. patent for method for expansion of immune cells
Mar 28
7:50pm ET
Pluri trading halted, news pending
Mar 28
7:18am ET
Pluri announces leadership from business verticals to attend conferences
Mar 27
7:06am ET
Pluri announces 1-for-8 reverse stock split
Mar 21
7:20am ET
Pluri addresses challenges revealed in ICO market report
Mar 11
7:15am ET
Pluri receives patent approval for 3D bioreactor technology
Mar 06
7:12am ET
Pluri appoints James Roosevelt, Jr. to advisory board
Feb 28
7:17am ET
Pluri CEO says entering 2024 with ‘significant momentum’
Feb 13
4:13pm ET
Pluri Inc. Secures $10 Million Share Sale Deal with A.G.P.
Jan 25
4:03am ET
Pluri Inc. Launches Sustainable Cell-Based Coffee Division
No recent press releases are available for PLUR
PLUR Financials
Key terms
Ad Feedback
PLUR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PLUR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range